心脏病

揭示心血管药物研发领域的新机遇

Beating cardiovascular disease requires a strategic, scientific approach; from tracking changing disease patterns in an aging population to developing cutting-edge approaches to disease management, it's no easy task. 因此，您需要一个值得信赖的、在小分子、设备治疗和生物制剂领域拥有丰富经验的合作伙伴，帮助您把握不断变化的市场格局。徕博科心血管专家的独特优势在于他们具备学术和行业经验，可为您提供富有远见的研究设计、预测性研究管理和卓越的运作服务。

Enable success by leveraging cardiology expertise and precision delivery

The primary reason for late-stage drug failure in cardiovascular trials is the inability to document improvement in outcomes. 因此，我们会在临床前试验阶段就与您及早开始合作，设计出以结果为导向的计划，帮助最小化风险，最大化您的成功几率。

• Get answers on safety earlier using our nonclinical cardiovascular safety assessment techniques and gain critical information for your “go/no-go” decision

• Add value to your study through our experience in cardiac ultrasound, magnetic resonance imaging, nuclear scanning and computed tomography (CT) angiography by capitalizing on our team of physicians who currently serve, or have served, as academic and core imaging laboratory directors

• Validate your drug’s safety and efficacy by proactively identifying biomarkers—assays, multicomponent panels or imaging-based—that are most predictive of risk or success

• 利用设计合理的试验展示心血管成果方面的实际改善，超越替代生物标记物的范畴。

Cardiology testing for your needs

我们针对心血管药物研发提供一整套的全面服务。 Our team of researchers can help you bring your next cardiovascular treatment to market.

• 中心实验室
• 扩展型实验室管理解决方案
  
• 体内药理学
• 先导药物优化非GLP毒理学
• 生物标记物解决方案中心

• 药理学
  
• 转化生物标记物

联系心血管专家

如果您有问题想联系我们的心脏病专家，请点击下面的按钮。

Cheerag Shirodaria，医学博士，MBA
副总裁兼心血管全球治疗领域负责人
牛津大学医院NHS信托基金会荣誉心脏病咨询专家

Dr. Cheerag Shirodaria joined Labcorp in 2011 and has pursued clinical cardiology and intensive cardiac care in a University of Oxford academic practice for more than a decade. As an interventional cardiologist, he provides expertise at Labcorp in all aspects of coronary artery disease, in particular acute coronary syndrome and device therapies. 他还是心脏成像领域的专家，完成了使用基于MRI的新型成像技术评估血管功能的博士论文。

Shirodaria博士还是牛津大学心脏CT成像项目的联合主管，目前仍然担任牛津大学的教职。 He has successfully designed and led a number of stem cell trials in the acute myocardial infarction population and is a member of the trial steering committee for numerous trials.

Jonathan Plehn，医学博士，美国心脏病学院院士
心血管医学部副总裁
德雷塞尔大学医学院临床教授

Dr. Jonathan Plehn moved to Labcorp from the Translational Medicine Branch of the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) in 2008, following over 25 years of academic medical practice and research. Plehn博士的研究重点是心脏衰竭、肺动脉高压和血管疾病。他曾在乔治·华盛顿大学、国家海军医疗中心和NHLBI主管心脏衰竭计划。 He is NIH-trained in cardiac MRI and has directed several academic cardiac ultrasound clinical and core laboratories, including establishing the first two-dimensional echo lab at the Framingham Heart Study.

作为研究者及管理人，Plehn博士参与过范围广泛的临床试验。 These have ranged from small proof of concept trials in rare diseases and novel molecules and biologics to Phase III pivotal cardioavascular outcomes trials. At the same time, he maintains his academic contacts continuing to publish and review manuscripts from top cardiology journals and is on the editorial board of the Journal of Cardiac Failure.